Ovid Therapeutics Inc. (OVID) Stock Score, Valuation & Financial Research
Ovid Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for OVID
Ovid Therapeutics Inc. currently has a Wall Street Score of 25/100. The stored market price is $2.68. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is -4.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What Ovid Therapeutics Inc. does
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent e
OVID financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $2.68
- Market capitalization:
- $500.2M
- Revenue:
- $1.6M
- Net income:
- $-34.5M
- Free cash flow:
- $-38.3M
- Cash:
- $11.3M
- Total debt:
- $12.7M
- EPS:
- -0.48
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.8%.
- Free cash flow is $-38.3M, showing cash burn in the current stored period.
- The balance sheet shows $11.3M of cash versus $12.7M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -4.7 points: OVID decreased 4.7 points because Asset declined by 8.6 points, Management declined by 40 points, Buffett declined by 7.3 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research OVID
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.